Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy

European Journal of Gynaecological Oncology

Volumn 34, Issue 6, 2013, Pages 540-544

  Bozkurt, M ^a   Yumru, A E ^a   Aral, I ^b  

^a ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

Adnexal mass; Benign and malign masses; CA125; CA15 3; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN 1; TUMOR MARKER;

ADNEXA DISEASE; ADULT; ARTICLE; BENIGN TUMOR; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FEMALE GENITAL TRACT CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT ADNEXAL MASS; OVARY CANCER; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AGED; BLOOD; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; UTERINE TUBE TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84898842808     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Issaq H. J., Waybright T. J., Veenstra T. D.: "Cancer biomaricer discovery: opportunities and pitfalls in analytical methods". Electrophoresis. 2011, 32, 967.
2. Freydanck MX, Laubender R. P., Rack B., Schuhmacher L., Jeschke U., Scholz G: "Two-marker combinations for preoperative discrimination of benign and malignant ovarian masses". Anticancer Res., 2012, 32, 2003.
3. Aggarwal P., Kehoe S.: "Serum tumour markers in gynaecological cancers". Maturitas, 2010, 67, 46.
4. Rodriguez N., Rauh-Hain J. A., Shoni M., Berkowitz R. S., Muto M. O., Feltmate C, Schorge J. O., et al:. "Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy". Gynecol. Oncol, 2012, 125, 362.
5. Dorigo O, Berek JS.: "Personalizing CA125 levels for ovarian cancer screening". Cancer Prev. Res. (Phila)., 2011, 9, 1356. doi: 10.1158/1940-6207.CAPR-11-0378.
6. Fung M. F., Bryson P., Johnston M, Chambers A., Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group.: "Screening postmenopausal women for ovarian cancer: a systematic review". J. Obstet. Gynaecol. Can., 2004, 26, 717.
7. Soper J. T., Hunter V. J., Daly L., Tanner M., Creasman W. T., Bast R. C. Jr.: "Preoperative serum tumor-associated antigen levels in women with pelvic masses". Obstet. Gynecol., 1990, 75, 249.
8. Gadducci A., Cosio S., Fanucchi A., Genazzani A. R.: "Serum CA125 and other tumor markers in ovarian cancer". In: Genazzani AR, Artini PG, (eds). Diagnostic procedure and latest development in gynecologic and obstetric investigation ESGOI 2001. Rome, CIC Edizioni Internazionali, 2001, 206.
9. Maggino T., Gadducci A., D'Addario V., Pecorelli S., Lissoni A., Stella M, et al. "Prospective multicenter study on CA125 in postmenopausal pelvic masses". Gynecol. Oncol., 1994, 54, 117.
10. Schutter E. M., Kenemans P., Sohn C, Kristen P., Crombach G., Westermann R., et al.: "Diagnostic value of pelvic examination, ultrasound, and serum CA125 in postmenopausal women with a pelvic mass. An international multicenter study". Cancer, 1994, 74, 1398.
11. Milojkovic M., Hrgovic Z., Hrgovic I., Jonat W., Maass N., Bukovic' D.: "Significance of CA125 serum level in discrimination between benign and malignant masses in the pelvis". Arch. Gynecol. Obstet., 2004, 269, 176.
12. Roman L. D., Muderspach L. I., Burnett A. F., Morrow C. P.: "Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?" J Reprod. Med., 1998, 43, 403.
13. Fi Mera P., Gadoducci A., Ferdegrum M., Bartolinii T., Fonta MV., Facchini V.: "Preoperative evaluation of CA 125 and CA 19-9 serum levels in patients with ovarian masses". Eur. J. Gynaecol. Oncol., 1988, 9, 291.
14. Scambia G., Benedetti Panici P., Baiocchi G., Perrone L., Greggi S., Mancuso S.: "CA 15-3 as a tumor marker in gynecological malignancies". Gynecol. Oncol., 1988, 30, 265.
15. Makar A. P., Kristensen G. B., Kaern J., Bormer O. P., Abeler V. M., Trope' C. G.: "Prognostic value of pre- and postoperative serum CA-125 levels in ovarian cancer new aspects and multivariate analysis". Obstet. Gynecol. 1992, 79, 1002.
16. Schutter E. M., Davelaar E. M., Van Kamp G. J, Verstraeten R. A., Kenemans P., Verheijen R. H.: "The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass". Am. J. Obstet. Gynecol., 2002, 187, 385.